98%
921
2 minutes
20
Little is known about the long-term course of polymorphic light eruption (PLE). To predict disease course, a questionnaire was sent to patients whose PLE had been diagnosed between March 1990 and December 2018 and documented in the Austrian Cooperative Registry for Photodermatoses. In January 2019, 205 PLE patients were contacted by mail and asked to complete a questionnaire on their disease course, including whether the skin's sun sensitivity had normalized (i.e., PLE symptoms had disappeared), improved, stayed the same, or worsened over time. Patients who reported normalization of sun sensitivity were asked to report when it had occurred. Ninety-seven patients (79 females, 18 males) returned a completed questionnaire. The mean (range) duration of follow-up from PLE onset was 29.6 (17-54) years for females and 29.4 (16-47) years for males. The disease disappeared in 32 (41%) females after 17.4 (2-41) years and in 4 (24%) males after 11.8 (5-26) years. Twenty-nine (37%) females and 6 (35%) males reported improvement of symptoms over time; 15 females (19%) and 7 males (41%) reported no change; and 3 females (4%) and no males reported worsening of symptoms. Kaplan-Meier analysis revealed that after 20 years 74% (95%CI, 64-82%) of patients still suffered from PLE. PLE lesion persistence (>1 week) tended to predict a prolonged course of PLE. PLE usually takes a long-term course over many years though in most patients its symptoms improve or disappear over time. How improvement relates to the pathophysiology of the disease remains to be determined.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323194 | PMC |
http://dx.doi.org/10.3389/fmed.2021.694281 | DOI Listing |
Clin Rheumatol
September 2025
Immunology Market Access, Johnson & Johnson, Horsham, PA, USA.
Introduction/objective: Oral glucocorticoids (OGC) are conventionally used as first-line treatment for dermatomyositis (DM) and polymyositis (PM). This study evaluated clinical and economic outcomes associated with long-term (LT) OGC use in DM/PM.
Methods: Adults with ≥ 2 medical claims of DM/PM 30‒365 days apart from January 1, 2016, to December 31, 2022, and ≥ 1 diagnosis code of a physician specialty of interest were selected from the MarketScan Commercial and Medicare Supplemental databases.
J Neurol Neurosurg Psychiatry
September 2025
Department of Neurology, Rostock University Medical Center, Rostock, Germany.
Background: Multiple sclerosis (MS) is the most common neuroimmunological disease in young adults. Data on its clinical onset before the age of 18 (paediatric-onset MS (POMS)) are limited.
Methods: This observational study present data on >1000 POMS compared with adult-onset MS (AOMS) and analysed patients regarding diagnostic delay, initial symptoms and long-term outcome using generalised additive models and adjustment for relevant confounders.
Cureus
August 2025
Department of Nursing Science, Hirosaki University Graduate School of Health Sciences, Hirosaki, JPN.
Objective In 2020, breast cancer was the most commonly diagnosed cancer among women in Japan. Its incidence begins to rise in the late twenties and reaches a first peak in the late forties. Therefore, fostering sustainable preventive health behaviors from a younger age is crucial.
View Article and Find Full Text PDFFront Allergy
August 2025
Internal Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of Targu Mures, Targu Mures, Romania.
Introduction: In the majority of patients with hereditary angioedema (HAE) due to C1-inhibitor deficiency (HAE-C1INH), effective long-term prophylactic (LTP) treatment can achieve complete disease control. Lanadelumab is one of the first-line option recommended for this purpose. Our study aimed to evaluate changes in disease control, quality of life, and attack frequency among Romanian HAE-C1INH patients, during the first year of treatment with lanadelumab.
View Article and Find Full Text PDFClin Cosmet Investig Dermatol
September 2025
Department of Dermatology, The Fifth People's Hospital of Hainan Province, Haikou, Hainan, People's Republic of China.
With the widespread long-term use of biologics in plaque psoriasis, reports of paradoxical eczema caused by interleukin-17A (IL-17A) monoclonal antibodies are increasing. This paradoxical eczema (PE) can occasionally require termination of biologic treatment, which may result in suboptimal management of psoriasis and increased risk of disease flare-ups. In the context of PE, therapeutic strategies should prioritize agents with dual efficacy against both the primary inflammatory process and paradoxical dermatitis, such as Janus kinase (JAK) inhibitors, which modulate key cytokine pathways implicated in both conditions.
View Article and Find Full Text PDF